Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
American Journal of Hematology · 2024-04 · 99 (4) · 697-718
DOI: 10.1002/ajh.27216 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 25.01.2024. Verfasst von Ayalew Tefferi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Polycythemia Vera, Thrombocytosis, Thrombosis. Die Arbeit wurde bisher 160-mal zitiert (Crossref) und nennt 166 Literaturangaben.
Abstract (Originalsprache)
Overview Essential thrombocythemia is a Janus kinase 2 ( JAK2 ) mutation‐prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, less frequently, by disease transformation into myelofibrosis (MF) or acute myeloid leukemia. Diagnosi s In addition to thrombocytosis (platelets ≥450 × 10 9 /L), formal diagnosis requires the exclusion of other myeloid neoplasms, including prefibrotic MF, polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts and thrombocytosis. Bone marrow morphology typically shows increased number of mature‐appearing megakaryocytes distributed in loose clusters. Genetics : Approximately 80% of patients express myeloproliferative neoplasm driver mutations ( JAK2 , CALR , MPL ), in a mutually exclusive manner; in addition, about 50% harbor other mutations, the most frequent being TET2 (9%–11%), ASXL1 (7%–20%), DNMT3A (7%), and SF3B1 (5%). Abnormal karyotype is seen in 35 years in younger patients. The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high‐, intermediate‐1‐, intermediate‐2‐, and low‐risk disease with corresponding median survivals of 8, 14, 21, and 47 years. Risk Factors for Thrombosis Four risk categories are considered: very low (age ≤60 years, no thrombosis history, JAK2 wild‐type), low (same as very low but JAK2 mutation present), intermediate (same as low but age >60 years), and high (thrombosis history or age >60 years with JAK2 mutation). Mutations and Prognosis MPL and CALR‐1 mutations have been associated with increased risk of MF transformation; spliceosome with inferior overall and MF‐free survival; TP53 with leukemic transformation, and JAK2 V617F with thrombosis. Leukemic transformation rate at 10 years is
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.
- Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
ORCID-Profile: Ayalew Tefferi, Alessandro Maria Vannucchi, Tiziano Barbui
Zitieren
APA
Tefferi, A., Vannucchi, A. M., & Barbui, T. (2024). Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology, 99(4), 697-718. https://doi.org/10.1002/ajh.27216
Vancouver
Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2024;99(4):697-718. doi:10.1002/ajh.27216
BibTeX
@article{Tefferi2024,
author = {Tefferi, Ayalew and Vannucchi, Alessandro Maria and Barbui, Tiziano},
title = {Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {4},
pages = {697--718},
doi = {10.1002/ajh.27216}
}
EUVIMED